D
Dafang Chen
Researcher at Peking University
Publications - 62
Citations - 890
Dafang Chen is an academic researcher from Peking University. The author has contributed to research in topics: Population & Medicine. The author has an hindex of 16, co-authored 50 publications receiving 729 citations. Previous affiliations of Dafang Chen include Chinese Ministry of Education.
Papers
More filters
Journal ArticleDOI
Incidence, Clinical Features and Impact on Anti-Tuberculosis Treatment of Anti-Tuberculosis Drug Induced Liver Injury (ATLI) in China
Penghui Shang,Yinyin Xia,Feiying Liu,Xiaomeng Wang,Yanli Yuan,Daiyu Hu,Dehua Tu,Yixin Chen,Peiyuan Deng,Shiming Cheng,Lin Zhou,Yu Ma,Lizhen Zhu,Weiwei Gao,Hongyuan Wang,Dafang Chen,Li Yang,Pingping He,Shanshan Wu,Shaowen Tang,Xiaozhen Lv,Zheng Shu,Yuan Zhang,Zhirong Yang,Yan Chen,Na Li,Feng Sun,Xiaoting Li,Ying-jian He,Paul Garner,Siyan Zhan +30 more
TL;DR: Given the incidence of ATLI and the size of TB population in China, the negative impact is substantial and more research and efforts are warranted in order to enhance the diagnosis and the prevention of AtLI.
Journal ArticleDOI
Selenium level in the environment and the population of Zhoukoudian area, Beijing, China.
TL;DR: The objective of this study was to detect the selenium level in the environment and the population of Zhoukoudian area, Beijing, and to discuss the influence of various factors on serum seenium level.
Journal ArticleDOI
Association of genetic polymorphisms and age-related macular degeneration in Chinese population.
Jun Tian,Wenzhen Yu,Xueying Qin,Kai Fang,Qing Chen,Jing Hou,Jing Hou,Juan Li,Dafang Chen,Yonghua Hu,Xiaoxin Li,Xiaoxin Li +11 more
TL;DR: Gene variants in CFH, ARMS2, and HTRA1 contribute to AMD in the Chinese population, and no relationship was found for AMD and the SNPs tested in complement 3 (C3); serpin peptidase inhibitor, clade G, member 1 (SERPING1); vascular endothelial growth factor (VEGF); cholesterol ester transfer protein (CETP); lipoprotein lipase (LPL); hepatic lipase
Journal ArticleDOI
Risperidone Maintenance Treatment in Schizophrenia: A Randomized, Controlled Trial
Chuanyue Wang,Yu-Tao Xiang,Zhuo-Ji Cai,Yong-Zhen Weng,Qijing Bo,Jingping Zhao,Tieqiao Liu,Gaohua Wang,Shi-Min Weng,Hongyan Zhang,Dafang Chen,Wai Kwong Tang,Gabor S. Ungvari +12 more
TL;DR: Patients who continued to receive the full risperidone dose used for their acute episode had fewer relapses than those who had dose reductions after 4 weeks or 26 weeks during the maintenance period and experienced greater reduction in the severity of psychotic symptoms.
Journal ArticleDOI
Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.
Jun Tian,Xueying Qin,Kai Fang,Qing Chen,Jing Hou,Jing Hou,Juan Li,Wenzhen Yu,Wenzhen Yu,Dafang Chen,Yonghua Hu,Xiaoxin Li,Xiaoxin Li +12 more
TL;DR: CFH, ARMS2 and HTRA1 genotypes may influence patient response to treatment with intravitreal bevacizumab for neovascular AMD.